We also showed that Smyd3 depletion sensitizes HPV-negative HSNCC mouse MOC1 tumors to anti-PD-1 therapy in vivo and that baseline SMYD3 mRNA expression levels predict response to neoadjuvant pembrolizumab in HPV-negative HNSCC patients. The gene discussed is SMYD3; the disease is head and neck squamous cell carcinoma.